NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UKONIQ (umbralisib tosylate) is an oral small-molecule PI3K delta inhibitor approved by the FDA in February 2021. It is indicated for treatment of hematologic malignancies, specifically chronic lymphocytic leukemia and marginal zone lymphoma. The drug works by selectively inhibiting phosphatidylinositol 3-kinase delta, a key enzyme in B-cell signaling pathways.
Peak9.1 years to LOE
Product is at peak commercial maturity with stable market presence; brand team likely operating at full capacity with 15 linked career opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UKONIQ offers career opportunity in a peak-stage oncology brand with strong patent protection and established commercial infrastructure. The 15 active job openings across multiple departments indicate a robust, growing team with clear pathways to leadership roles.
Assoc. DirectorMedical Science Liaison
Worked on UKONIQ at TG Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.